{"id":11427,"date":"2026-02-18T08:15:42","date_gmt":"2026-02-18T08:15:42","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/11427\/"},"modified":"2026-02-18T08:15:42","modified_gmt":"2026-02-18T08:15:42","slug":"acinetobacter-infections-pipeline-expands-as-7-pharma-companies-progress-novel-therapies-toward-market-entry-finds-delveinsight","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/11427\/","title":{"rendered":"Acinetobacter Infections Pipeline Expands as 7+ Pharma Companies Progress Novel Therapies Toward Market Entry, Finds DelveInsight"},"content":{"rendered":"

\"\"<\/a><\/p>\n

“Acinetobacter Infections \u2013 Pipeline Insight, 2026”<\/p>\n

DelveInsight\u2019s \u201cAcinetobacter Infections \u2013 Pipeline Insight, 2026\u201d report provides comprehensive insights about 8+ companies, including Omnix Medical, Roche, Telum Therapeutics, Spero Therapeutics, VenatoRx Pharmaceuticals, ABAC Therapeutics, and others, developing 10+ pipeline drugs in the Acinetobacter Infections pipeline landscape.<\/p>\n

DelveInsight\u2019s \u201cAcinetobacter Infections \u2013 Pipeline Insight, 2026\u201d report provides comprehensive insights about 8+ companies developing 10+ pipeline drugs in the Acinetobacter Infections pipeline landscape. It covers the Acinetobacter Infections pipeline drug profiles, including clinical and nonclinical stage products, along with therapeutics assessment by product type, stage, route of administration, and molecule type, and further highlights inactive pipeline products in this space.\u200b<\/p>\n

Explore the latest breakthroughs in the Acinetobacter Infections treatment landscape. Learn more about the evolving Acinetobacter Infections pipeline today @ https:\/\/www.delveinsight.com\/report-store\/acinetobacter-infections-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr<\/a><\/p>\n

\u200bKey Takeaways from the Acinetobacter Infections Pipeline Report\u200b<\/p>\n

In July 2025, Brii Biosciences licensed BRII-693 (targeting Acinetobacter baumannii and Pseudomonas infections) to Joincare Group for exclusive development and commercialization in Greater China.<\/p>\n

In April 2025, Shionogi signed an exclusive licensing agreement with Link Healthcare for cefiderocol development and commercialization in Australia and New Zealand, targeting Acinetobacter-resistant infections.\u200b<\/p>\n

The leading Acinetobacter infections companies include Omnix Medical, Roche, Telum Therapeutics, Spero Therapeutics, VenatoRx Pharmaceuticals, ABAC Therapeutics, and others are evaluating their lead assets to improve the Acinetobacter infections treatment landscape.\u200b<\/p>\n

Key Acinetobacter infection pipeline therapies in various stages of development include OMN6, RG6006, SPR-206, Research programme: PBP inhibitor program, and others.\u200b<\/p>\n

Download for updates and the latest revolution in Acinetobacter Infections care @ Acinetobacter Infections Clinical Trials Assessment<\/a><\/p>\n

Acinetobacter Infections Emerging Drugs Profile\u200b<\/p>\n

OMN6 is a novel, first-in-class antimicrobial peptide (AMP) based on insect host defense peptides. Its mechanism of action (MoA) is based on disruption of bacterial cell membranes and is therefore effective regardless of bacterial genotype or resistance phenotype, and unlike conventional bacteriostatic antibiotics, it is fast acting and bactericidal. The US Food and Drug Administration (FDA) has also granted fast-track designation to OMN6. Currently, the drug is in Phase II stage of its development for the treatment of Acinetobacter Infections.<\/p>\n

BV100 has a novel mode of action addressing carbapenem resistant Acinetobacter baumannii (CRAB) lung and blood stream infections. Currently, the drug is in Phase II stage of its development for the treatment of Acinetobacter Infections.<\/p>\n

MRX-8 is a next-generation polymyxin antibiotic developed by MicuRx to target multidrug-resistant Gram-negative bacteria, including carbapenem-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, and other resistant pathogens. Currently, the drug is in Phase I stage of its development for the treatment of Acinetobacter Infections.<\/p>\n

For more information on the Acinetobacter Infections Emerging Drugs Profile, download DelveInsight\u2019s comprehensive Acinetobacter Infections Pipeline Insight report<\/a>.\u200b<\/p>\n

The Acinetobacter Infections Pipeline Report Provides\u200b<\/p>\n

Detailed insights about companies developing therapies for Acinetobacter Infections, with aggregate therapies developed by each company.\u200b<\/p>\n

Different therapeutic candidates, segmented into early-stage, mid-stage, and late-stage of development for Acinetobacter Infections treatment.\u200b<\/p>\n

Acinetobacter Infections companies that are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.\u200b<\/p>\n

Acinetobacter Infections drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.\u200b<\/p>\n

Detailed analysis of collaborations (company\u2013company and company\u2013academia), licensing agreements, and financing details for future advancement of the Acinetobacter Infections market.\u200b<\/p>\n

Learn more about Acinetobacter Infections Drugs opportunities in our comprehensive Acinetobacter Infections pipeline report @ Acinetobacter Infections Unmet Needs<\/a><\/p>\n

Acinetobacter Infections Companies\u200b<\/p>\n

There are 7+ key companies, such as Omnix Medical, Roche, Telum Therapeutics, Spero Therapeutics, VenatoRx Pharmaceuticals, ABAC Therapeutics, and others, developing therapies for Acinetobacter Infections.\u200b<\/p>\n

DelveInsight\u2019s Acinetobacter Infections pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as:\u200b<\/p>\n

Oral<\/p>\n

Intravenous<\/p>\n

Subcutaneous<\/p>\n

Parenteral<\/p>\n

Topical<\/p>\n

Acinetobacter Infections products have been categorized under various Molecule types such as:\u200b<\/p>\n

Discover the latest advancements in Acinetobacter Infections treatment by visiting our website. Stay informed @ Acinetobacter Infections Market Drivers and Barriers, and Future Perspectives<\/a>.\u200b<\/p>\n

Scope of the Acinetobacter Infections Pipeline Report\u200b<\/p>\n

Coverage: Global\u200b<\/p>\n

Acinetobacter Infections companies: Omnix Medical, Roche, Telum Therapeutics, Spero Therapeutics, VenatoRx Pharmaceuticals, ABAC Therapeutics, and others.\u200b<\/p>\n

Acinetobacter Infections Therapies: OMN6, RG6006, SPR-206, Research programme: PBP inhibitor program, and others.\u200b<\/p>\n

Acinetobacter Infections Therapeutic Assessment by Product Type: Mono, Combination, Mono\/Combination\u200b<\/p>\n

Acinetobacter Infections Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III\u200b<\/p>\n

Table of Contents\u200b<\/p>\n

Introduction\u200b<\/p>\n

Executive Summary\u200b<\/p>\n

Acinetobacter Infections: Overview\u200b<\/p>\n

Pipeline Therapeutics\u200b<\/p>\n

Therapeutic Assessment\u200b<\/p>\n

Acinetobacter Infections \u2013 DelveInsight\u2019s Analytical Perspective\u200b<\/p>\n

Late Stage Products (Phase III)\u200b<\/p>\n

Mid Stage Products (Phase II)\u200b<\/p>\n

Early Stage Products (Phase I)\u200b<\/p>\n

Preclinical and Discovery Stage Products\u200b<\/p>\n

Inactive Products\u200b<\/p>\n

Acinetobacter Infections Key Companies\u200b<\/p>\n

Acinetobacter Infections Key Products\u200b<\/p>\n

Acinetobacter Infections Unmet Needs\u200b<\/p>\n

Acinetobacter Infections Market Drivers and Barriers\u200b<\/p>\n

Acinetobacter Infections Future Perspectives and Conclusion\u200b<\/p>\n

Acinetobacter Infections Analyst Views\u200b<\/p>\n

Appendix\u200b<\/p>\n

Media Contact
Company Name: DelveInsight Business Research LLP<\/a>
Contact Person: Arpit Anand
Email: Send Email<\/a>
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https:\/\/www.delveinsight.com\/consulting\/due-diligence-services<\/a><\/p>\n

Press Release Distributed by ABNewswire.com<\/a>
\n
To view the original version on ABNewswire visit: Acinetobacter Infections Pipeline Expands as 7+ Pharma Companies Progress Novel Therapies Toward Market Entry, Finds DelveInsight | Omnix Medical, Roche, Telum Therapeutics, Spero Therapeutics<\/a>\n<\/p>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"“Acinetobacter Infections \u2013 Pipeline Insight, 2026” DelveInsight\u2019s \u201cAcinetobacter Infections \u2013 Pipeline Insight, 2026\u201d report provides comprehensive insights about…\n","protected":false},"author":2,"featured_media":1372,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[124],"tags":[1771,134],"class_list":{"0":"post-11427","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-roche","8":"tag-n-a","9":"tag-roche"},"share_on_mastodon":{"url":"","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/11427","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=11427"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/11427\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/1372"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=11427"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=11427"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=11427"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}